Published in Exp Hematol on July 15, 2009
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood (2014) 1.44
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia (2014) 1.08
C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol (2014) 0.79
A myeloid tumor suppressor role for NOL3. J Exp Med (2017) 0.75
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell (2013) 3.31
NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature (2013) 2.63
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 2.37
Prone vs supine positioning for breast cancer radiotherapy. JAMA (2012) 2.32
Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J Exp Med (2006) 2.18
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Survival in familial dysautonomia: Impact of early intervention. J Pediatr (2002) 1.98
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood (2003) 1.76
Dexmedetomidine for awake carotid endarterectomy: efficacy, hemodynamic profile, and side effects. J Neurosurg Anesthesiol (2004) 1.73
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Multiploid inheritance of HIV-1 during cell-to-cell infection. J Virol (2011) 1.66
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood (2004) 1.55
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem (2006) 1.55
Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. Clin Auton Res (2005) 1.52
Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys (2004) 1.51
The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood (2011) 1.50
The legitimacy of leadership in international climate change negotiations. Ambio (2012) 1.50
Clarifying the use of ruxolitinib in patients with myelofibrosis. Oncology (Williston Park) (2013) 1.49
Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood (2009) 1.48
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
Fetal cells traffic to injured maternal myocardium and undergo cardiac differentiation. Circ Res (2011) 1.45
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood (2006) 1.42
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol (2003) 1.42
Oncogene-mediated alterations in chromatin conformation. Proc Natl Acad Sci U S A (2012) 1.40
High performance of the BCR/ABL-extra sensitive (ES) probe for detection of der(9q) deletion in t(9;22) (q34;q11.2). Cancer Genet Cytogenet (2002) 1.39
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood (2005) 1.35
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res (2012) 1.35
Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol (2006) 1.29
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood (2012) 1.26
Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol (2007) 1.23
Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nat Commun (2012) 1.21
Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J Am Coll Cardiol (2010) 1.20
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood (2013) 1.19
Surgical management of complications after hearing aid fitting. Laryngoscope (2004) 1.19
TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.19
Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res (2009) 1.17
Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood (2006) 1.17
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci (2008) 1.14
Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity. Br J Haematol (2012) 1.14
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood (2009) 1.13
Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol (2005) 1.13
Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab (2013) 1.13
Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood (2013) 1.12
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat (2010) 1.12
Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol (2011) 1.12
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis (2007) 1.12
Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol (2006) 1.12
Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol (2010) 1.12
Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. Am J Physiol Endocrinol Metab (2012) 1.12
CT scan screening for lung cancer: risk factors for nodules and malignancy in a high-risk urban cohort. PLoS One (2012) 1.12
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood (2013) 1.11
Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol (2008) 1.10
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol (2012) 1.10
Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. Int J Radiat Oncol Biol Phys (2012) 1.10
Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest (2014) 1.09
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
Hyperhomocysteinemia promotes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue. J Biol Chem (2013) 1.08
In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother (2009) 1.07
Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. Blood (2011) 1.06
HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells. Kidney Int (2008) 1.05
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res (2007) 1.04
The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res (2010) 1.03
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol (2008) 1.02
Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arterioscler Thromb Vasc Biol (2012) 1.01
Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res (2009) 1.01
Kinetin in familial dysautonomia carriers: implications for a new therapeutic strategy targeting mRNA splicing. Pediatr Res (2009) 1.00
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood (2013) 0.99
EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res (2013) 0.99
High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Res (2010) 0.97
Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am J Clin Pathol (2006) 0.97
Liver transplantation in the management of porphyria. Hepatology (2014) 0.97
Lack of major involvement of human uroplakin genes in vesicoureteral reflux: implications for disease heterogeneity. Kidney Int (2004) 0.96
Evaluating Academic Scientists Collaborating in Team-Based Research: A Proposed Framework. Acad Med (2015) 0.96